RxDoctor Payments Data

Jennifer McCallum, MD

Rheumatology · Little Rock, ARNPI 1760695944

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $902 of the $1,012 with a category attached, or 89.1%. 5 manufacturers reported payments, led by Amgen at 39.2% of the total. Reporting peaked in 2024 at $410 and has fallen 68.2% since, to $131 in 2025. That places this record below the midpoint for rheumatology clinicians in AR, where the typical reported total is $4,419.

$1,012in general payments, 2019–2025

Across 49 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$396
  • GSK$259
  • AbbVie$153
  • Pfizer$135
  • E.r. Squibb & Sons, L.L.C.$69

What the payments were for

  • Food & beverage$90289%
  • Education$11011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)16$396
GSK15$259
AbbVie7$153
Pfizer8$135
E.r. Squibb & Sons, L.L.C.3$69

How this compares

$1,012 in reported general payments places this provider in the 35th percentile of 48 rheumatology providers in Arkansas.

See all rheumatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$414,590
Medicare patients
178
Services billed
26,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept47$395,278
Humira(Cf) PenAdalimumab34$232,237
RinvoqUpadacitinib17$109,345
Humira PenAdalimumab11$85,511
BenlystaBelimumab13$73,170
SimponiGolimumab12$71,820
SavellaMilnacipran Hcl24$17,260
Hydroxychloroquine Sulfate462$15,974
MethotrexateMethotrexate Sodium287$5,379
Leflunomide85$4,161
Prednisone293$1,666
Sulfasalazine86$1,583
Gabapentin74$1,318
Pregabalin39$815
Tramadol Hcl85$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Savella$153$126,60641 claims
GSKBenlysta$259$73,17013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 48 rheumatology providers in Arkansas.

Other rheumatology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →